Clinical trials in Meldola – page 23

Study on Doxorubicin Hydrochloride and Trabectedin for Patients with Recurrent Ovarian Cancer

Study on Doxorubicin Hydrochloride and Trabectedin for Patients with Recurrent Ovarian Cancer

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

Study on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment

Study on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment

Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

Study on Radium-223, Docetaxel, and Prednisone for Patients with Bone-Only Metastatic Castration-Resistant Prostate Cancer

Study on Radium-223, Docetaxel, and Prednisone for Patients with Bone-Only Metastatic Castration-Resistant Prostate Cancer

Study of Subcutaneous Nivolumab for Patients with Previously Treated Advanced or Metastatic Clear Cell Kidney Cancer

Study of Subcutaneous Nivolumab for Patients with Previously Treated Advanced or Metastatic Clear Cell Kidney Cancer

Study of venetoclax with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed patients with intermediate or high-risk Acute Myeloid Leukemia

Study of venetoclax with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed patients with intermediate or high-risk Acute Myeloid Leukemia

Study Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant

Study Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Study of liposomal annamycin and cytarabine combination for patients with acute myeloid leukemia (AML) who are newly diagnosed or have not responded to previous treatment

Study of liposomal annamycin and cytarabine combination for patients with acute myeloid leukemia (AML) who are newly diagnosed or have not responded to previous treatment